Breckenridge obtains FDA OK for generic Eliquis
Eliquis had a market value of $14 billion during the 12 months ended May 2021, according to industry data.
The Food and Drug Administration has cleared Breckenridge’s apixaban tablets.
The medication is used to reduce the risk of stroke and blood clots in people who have atrial fibrillation, a type of irregular heartbeat, not caused by a heart valve problem.
Apixaban is the generic of Bristol Myers-Squibbs’ Eliquis. It was developed by Towa Pharmaceutical Europe, in its manufacturing facility located in Martorelles, Spain.
Eliquis had a market value of $14 billion during the 12 months ended May 2021, according to industry data.